Recursion Pharmaceuticals Inc (RXRX)
6.36
-0.55
(-7.96%)
USD |
NASDAQ |
Nov 15, 10:33
Recursion Pharmaceuticals Free Cash Flow (Quarterly): -63.79M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -63.79M |
| June 30, 2024 | -86.40M |
| March 31, 2024 | -108.95M |
| December 31, 2023 | -76.49M |
| September 30, 2023 | -73.75M |
| June 30, 2023 | -71.44M |
| March 31, 2023 | -78.66M |
| December 31, 2022 | -52.73M |
| September 30, 2022 | -63.10M |
| June 30, 2022 | -78.10M |
| Date | Value |
|---|---|
| March 31, 2022 | 73.05M |
| December 31, 2021 | -65.62M |
| September 30, 2021 | -42.75M |
| June 30, 2021 | -39.86M |
| March 31, 2021 | -50.17M |
| December 31, 2020 | 3.982M |
| September 30, 2020 | -20.28M |
| June 30, 2020 | -17.33M |
| March 31, 2020 | -18.50M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-108.95M
Minimum
Mar 2024
73.05M
Maximum
Mar 2022
-48.99M
Average
-63.10M
Median
Sep 2022
Free Cash Flow (Quarterly) Benchmarks
| Revance Therapeutics Inc | -41.15M |
| Eli Lilly and Co | -458.90M |
| Pfizer Inc | 6.063B |
| Twist Bioscience Corp | -7.343M |
| NovaBay Pharmaceuticals Inc | -2.063M |